Sanofi Consumer

Who are the top shareholders of the Sanofi Consumer?

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V. with 60.4%, Life Insurance Corporation of India at 5.66%, and individual investors with 6.58%. Additionally, 18 mutual fund schemes hold 15.09%, while 102 foreign institutional investors have a total of 4.53%.

The top shareholders of Sanofi Consumer include Opella Healthcare Participations B.V., which holds the largest stake at 60.4%. Other significant shareholders are the Life Insurance Corporation of India, with a holding of 5.66%, and individual investors collectively owning 6.58%. Additionally, the company has 18 mutual fund schemes holding a combined 15.09% and 102 foreign institutional investors (FIIs) with a total holding of 4.53%. There are no pledged promoter holdings reported.

Has Sanofi Consumer declared dividend?

Yes, Sanofi Consumer Healthcare India Ltd has declared a 550% dividend, amounting to ₹55 per share, with an ex-date of April 17, 2025. However, total returns over the past year and longer periods have been stagnant, showing no price or dividend growth.

Sanofi Consumer Healthcare India Ltd has declared a 550% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 550%<BR>- Amount per share: 55<BR>- Ex-date: 17 Apr 25<BR><BR>Dividend Yield: 1.08%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.2%, the dividend return was 1.14%, resulting in a total return of 6.34%.<BR><BR>In the last 1 year, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 2 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 3 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the last 5 years, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sanofi Consumer has declared a significant dividend, the total returns over longer periods indicate a lack of growth in price and dividends, suggesting a mixed performance in terms of shareholder returns.

Is Sanofi Consumer overvalued or undervalued?

As of April 19, 2025, Sanofi Consumer is considered very expensive and overvalued with a PE ratio of 57.64, significantly higher than its peers, and has underperformed the Sensex with a recent return of -6.91%.

As of 19 April 2025, the valuation grade for Sanofi Consumer has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a price-to-earnings (PE) ratio of 57.64, a price-to-book value of 42.77, and an EV to EBITDA ratio of 41.78. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Sanofi Consumer's PE ratio is notably higher than Sun Pharmaceutical Industries Ltd. at 35.25 and Cipla Ltd. at 22.99, both of which are considered attractive. Furthermore, the PEG ratio for Sanofi is 0.00, indicating no growth expectations, which contrasts sharply with the more reasonable valuations of its competitors. Recent stock performance shows that Sanofi has underperformed the Sensex over the past week, with a return of -6.91% compared to the Sensex's 1.35%. This reinforces the notion that the stock may be overvalued in the current market context.

Who are the peers of the Sanofi Consumer?

Sanofi Consumer's peers include Sai Life, Blue Jet Health, Caplin Point Lab, Sanofi India, Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, Acutaas Chemical, and Shilpa Medicare. Blue Jet Health has the highest 1-year return at 128.90%, while Sanofi India has the lowest at -7.90%.

Peers: The peers of Sanofi Consumer are Sai Life, Blue Jet Health, Caplin Point Lab, Sanofi India, Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, Acutaas Chemical, and Shilpa Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi India and P & G Health Ltd, while Good management risk is found at Sai Life, Blue Jet Health, Caplin Point Lab, Alivus Life, Granules India, Marksans Pharma, and Acutaas Chemical, and Average management risk is noted at Shilpa Medicare. Growth is rated as Good for Sai Life and Acutaas Chemical, Average for Caplin Point Lab, and Below Average for Blue Jet Health, Sanofi India, Alivus Life, Granules India, Marksans Pharma, and P & G Health Ltd. Capital Structure is Excellent for Blue Jet Health, Caplin Point Lab, Sanofi India, Alivus Life, Granules India, Marksans Pharma, P & G Health Ltd, and Acutaas Chemical, while Average is noted for Sai Life and Below Average for Shilpa Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 128.90%, while Sanofi India has the lowest at -7.90%, with Sanofi Consumer's 1-year return being N/A. Additionally, Granules India and Sanofi India have negative six-month returns.

What does Sanofi Consumer do?

Sanofi Consumer Healthcare India Ltd, established in May 2023 after a demerger from Sanofi India Limited, focuses on the Consumer Healthcare sector with recent net sales of ₹1,726 Cr and a net profit of ₹500 Cr as of March 2025. The company has a market cap of ₹11,988 Cr and key metrics include a P/E ratio of 59.00 and a return on equity of 74.20%.

Overview:<BR>Sanofi Consumer Healthcare India Ltd operates in the Pharmaceuticals & Biotechnology industry as a mid-cap company focused on establishing a standalone Consumer Healthcare business.<BR><BR>History:<BR>The company was incorporated on May 10, 2023, following the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL). The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,726 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 500 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 11,988 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 59.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 1.08% <BR>Debt-Equity: -1.20 <BR>Return on Equity: 74.20% <BR>Price to Book: 43.26 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Sanofi Consumer?

As of 24th July, Sanofi Consumer Healthcare India Ltd has a market capitalization of 11,412.00 Cr, with recent net sales of 667.60 Cr and net profit of 168.30 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Sanofi Consumer Healthcare India Ltd has a market capitalization of 11,412.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 667.60 Cr, while the sum of Net Profit for the same period is 168.30 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is December 2024, with Shareholder's Funds amounting to 273.00 Cr and Total Assets valued at 425.10 Cr.

How has been the historical performance of Sanofi Consumer?

Sanofi Consumer reported net sales of 724.50 crore and a profit after tax of 181.00 crore for the year ending December 2024, reflecting strong growth. Shareholder's funds increased to 273.00 crore, and cash and bank balances rose significantly to 326.90 crore.

Answer:<BR>The historical performance of Sanofi Consumer for the year ending December 2024 shows significant growth in various financial metrics compared to the previous year.<BR><BR>Breakdown:<BR>In December 2024, Sanofi Consumer reported net sales of 724.50 crore, with total operating income also at 724.50 crore. The total expenditure, excluding depreciation, was 453.90 crore, leading to an operating profit (PBDIT) of 283.60 crore. After accounting for interest and exceptional items, the profit before tax stood at 246.80 crore, resulting in a profit after tax of 181.00 crore. The earnings per share (EPS) was reported at 78.7, with a PAT margin of 24.98%. On the balance sheet, shareholder's funds increased to 273.00 crore from 207.60 crore in the previous year, while total liabilities rose to 425.10 crore from 343.50 crore. The total assets also increased to 425.10 crore, with cash and bank balances significantly rising to 326.90 crore from just 1.60 crore in December 2023. The cash flow from operating activities was 439.00 crore, contributing to a net cash inflow of 325.00 crore for the year.

Is Sanofi Consumer technically bullish or bearish?

As of December 2, 2025, Sanofi Consumer's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, and moving averages, despite some divergence in longer-term perspectives indicated by Dow Theory.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend. The Dow Theory indicates a mildly bearish stance on the weekly but is mildly bullish on the monthly, suggesting some divergence in longer-term perspectives. Overall, the bearish indicators dominate the current technical outlook for Sanofi Consumer.

When is the next results date for Sanofi Consumer Healthcare India Ltd?

The next results date for Sanofi Consumer Healthcare India Ltd is April 28, 2026.

The next results date for Sanofi Consumer Healthcare India Ltd is scheduled for April 28, 2026.

Are Sanofi Consumer Healthcare India Ltd latest results good or bad?

Sanofi Consumer Healthcare India Ltd's latest Q4 FY26 results are generally positive, with a 35.60% year-on-year profit increase and strong sales growth, despite a seasonal decline. However, the stock's high valuation may raise concerns for potential investors.

Sanofi Consumer Healthcare India Ltd's latest results for Q4 FY26 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹67.80 crores, which is a 35.60% increase year-on-year and a slight 1.95% increase from the previous quarter. This reflects strong profitability and operational efficiency.<BR><BR>Net sales for the quarter were ₹229.20 crores, showing a robust year-on-year growth of 32.79% from ₹172.60 crores in Q4 FY25, although there was a sequential decline of 8.69% from ₹251.00 crores in Q3 FY26. This decline is typical for the consumer healthcare segment due to seasonal factors, but the company managed to maintain a healthy PAT margin of 29.58%, which is the highest in its recent history.<BR><BR>Additionally, the return on equity (ROE) stands at an exceptional 91.45%, indicating strong capital efficiency. The company operates with zero debt, which provides it with significant financial flexibility.<BR><BR>While the results indicate strong operational performance, the stock is trading at a premium valuation, which raises questions about sustainability. The high price-to-earnings ratio of 46 times and price-to-book value of 42 times suggest that investors are paying a premium for the company's growth potential.<BR><BR>In summary, Sanofi Consumer Healthcare's latest results highlight strong profitability and operational metrics, but the elevated valuations may warrant caution for potential investors.

Should I buy, sell or hold Sanofi Consumer Healthcare India Ltd?

Why is Sanofi Consumer Healthcare India Ltd falling/rising?

As of 30-Apr, Sanofi Consumer Healthcare India Ltd's stock price is 4,764.65, down 0.72% after a trend reversal. Despite strong recent performance and financial health, long-term growth concerns and high valuation metrics suggest potential challenges ahead.

As of 30-Apr, Sanofi Consumer Healthcare India Ltd's stock price is currently at 4,764.65, reflecting a decrease of 34.5 points or 0.72%. The stock has recently experienced a trend reversal, having fallen after five consecutive days of gains. Despite this recent decline, the stock has shown positive performance over the past week, rising by 3.80%, while the benchmark Sensex has decreased by 0.97%. Over the past month, the stock has increased by 10.96%, outperforming the Sensex, which gained 6.90%.<BR><BR>The company's financial health appears strong, with a high return on equity (ROE) of 76.98% and being net-debt free. Additionally, Sanofi has reported positive results for the last three consecutive quarters, with net sales growing by 39.88% in the latest six months and achieving the highest profit after tax (PAT) of Rs 67.80 crore. However, the stock's long-term growth prospects are concerning, as net sales have only grown at an annual rate of 10.10% and operating profit at 5.70% over the last five years. This has led to a high valuation, with a price-to-book value of 42.7, and a PEG ratio of 2.6, indicating it may be considered expensive.<BR><BR>Furthermore, the stock has consistently underperformed against benchmarks over the last three years, generating a return of -3.49% in the past year, while profits have remained stagnant. This underperformance, combined with the recent price decline, suggests that while there are positive short-term indicators, the long-term outlook and valuation concerns are contributing to the current downward movement in the stock price.

Which are the latest news on Sanofi Consumer?